[COMB2014]鼓励患者直面乳腺癌遗传咨询——Wong Seng Weng教授访谈

作者:  黄醒荣   日期:2014/8/26 18:43:55  浏览量:64736

肿瘤瞭望版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

编者按:“第二届乳腺癌个体化治疗大会”于8月1~3日在北京顺利召开。会上,来自新加坡的Wong Seng Weng教授作了精彩演讲。Wong Seng Weng是伊丽莎白医疗癌症中心肿瘤学专家及内科主任顾问,擅长成人肿瘤的诊断与治疗,尤其在乳腺肿瘤、肺部肿瘤以及胃肠道肿瘤上有着自己独到的见解。《肿瘤瞭望》就乳腺的诊疗进展、遗传咨询和脑转移等问题采访了Wong教授。

  <Oncology Frontier>: What is the advisability of screening for brain metastases both in HER2-positive and HER2-negative metastatic breast cancer patients?

  《肿瘤瞭望》:对HER2阳性和HER2阴性转移性乳腺癌患者,进行脑转移筛查的可行性如何?

  Dr Wong: We have noticed certain groups of patients are more at risk of developing brain metastases. One of those is the HER2 overexpression tumors. For the HER2-negative cancers, we have noticed that it is the triple-negatives (negative for ER, PR and HER2) who are at increased risk of developing brain metastases. Many clinicians feel that it is reasonable for them to screen for occult metastases in the brain with a routine MRI at the time of diagnosis. I wouldn’t say that is wrong but we don’t have strong data to prove such an approach will improve patient outcomes for disease-free survival or overall survival.  Certainly, at the recently concluded Advanced Breast Cancer Consensus Conference in Lisbon, the general consensus was no, even in the selective high-risk groups of HER2-positive or triple-negative breast cancer patients.The experts’ opinion is that we will still not recommend routine screening for brain metastases by MRI. I think it is something that we not apply across the board but select patients if we choose to screen.

  Wong教授:我们发现部分乳腺癌患者发生脑转移的风险更大。其中一部分是HER2过表达的患者。对于HER2阴性乳腺癌患者,我们发现三阴乳腺癌患者(ER、PR和HER2均阴性)发生脑转移的风险增加。不少医生认为对于这些患者,诊断时使用MRI对潜在的脑转移病灶进行筛查是有必要的。我不敢说这种观点是错误的,但目前没有充分的数据支持这种做法可以改善患者的无肿瘤生存期和总生存期。当然,最近在里斯本闭幕的晚期乳腺癌共识会议上得出的观点是不支持这一做法的,即便对于部分高危HER2阳性患者和三阴乳腺癌患者,也不推荐进行筛查。专家的意见是仍不推荐使用MRI对脑转移进行筛查。

 

 

上一页  [1]  [2]  [3]  

版面编辑:张楠  责任编辑:吉晓蓉

本内容仅供医学专业人士参考


乳腺癌遗传咨询脑转移筛查

分享到: 更多